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Introduction
Among the pyrimidine analogs, gemcitabine (2′,2′-difluoro-
deoxycytidine, dFdC; Gemzar®) is one the most widely 
used drugs in clinical oncology and ranked the third anti-
cancer agent prescribed worldwide. It is a cytidine analog, 
where two fluorine atoms have replaced the hydroxyl on 
the ribose. In particular, gemcitabine is a mainstay in pan-
creatic adenocarcinoma [1, 2] and is widely prescribed to 
treat a variety of other solid tumors such as breast, ovarian, 
bladder or non-small-cell lung (NSCLC) cancers [3, 4]. In 
addition to solid tumors, gemcitabine is indicated as well 
in several hematological disorders such as acute leukemia 
[5]. Beyond adult patients, gemcitabine can be an attractive 
option in pediatric cancers because its toxic profile is usu-
ally considered as mild as compared with other cytotoxic 
drugs.
After administration and taken up by the cancer cell, 
gemcitabine undergoes an initial phosphorylation by deox-
ycytidine kinase (dCK) and to a lower extent by the extra-
mitochondrial thymidine kinase 2, followed by a series of 
phosphorylation steps in order to be incorporated into both 
DNA and RNA as its active phosphorylated form gemcit-
abine triphosphate (dFdCTP) [6]. Additionally, gemcit-
abine diphosphate (dFdCDP) inhibits ribonucleotide reduc-
tase (RR), an enzyme in the nucleotide pathway critical for 
the cancer cell to manage its pools of deoxynucleotides. 
The clearance of gemcitabine is mostly driven by rapid and 
extensive inactivation by cytidine deaminase (CDA) to its 
primary metabolite 2′,2′-difluoro-deoxyuridine (dFdU); 
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CDA is expressed ubiquitously at high levels in both 
plasma and the liver, [7]. A 24-h hepatic artery infusion of 
gemcitabine to the liver underlined the important role for 
liver CDA-mediated catabolism to dFdU, since the Cmax 
and area-under-curve of dFdU were similar for the hepatic 
artery infusion and a 24-h intravenous infusion of gemcit-
abine, while gemcitabine plasma levels were much lower 
after the hepatic artery infusion [8]. Figure 1 briefly sum-
marizes these main steps of gemcitabine metabolism and 
mechanisms of action.
Because gemcitabine is the backbone of numerous reg-
imens, several studies have tried to identify molecular or 
genetic determinants of response, both at the somatic and 
the constitutional levels [9]. In addition, recent efforts have 
been made to improve the metabolism and pharmacokinet-
ics (DM-PK) profile of gemcitabine, creating novel chemi-
cal derivatives, prodrugs or nanomedicine forms [10].
Gemcitabine pharmacokinetics 
and pharmacodynamics
Because of its hydrophilic nature, gemcitabine does not 
readily cross the membrane by diffusion, and it is trans-
ported into the cells by membrane nucleoside transporters 
[11]. Following cellular uptake, gemcitabine is phosphoryl-
ated to its active diphosphate (dFdCDP) and triphosphate 
(dFdCTP) metabolites, which inhibit RR and DNA syn-
thesis, respectively [12]. dCK is the rate-limiting enzyme 
in the biotransformation of nucleoside analogs, and sev-
eral studies have suggested that dCK is a limiting factor 
for gemcitabine activity, because its deficiency/modula-
tion is critically involved in acquired resistance in differ-
ent in vitro models [13, 14]. Moreover, pretreatment dCK 
expression level could be used as a predictive parameter 
of tumor sensitivity, as observed with a clear correlation 
Fig. 1  Gemcitabine (dFdC) patterns and mechanisms of action. CDA 
cytidine deaminase, dCK deoxycytidine kinase, NMPK nucleotide 
monophosphate kinase, NDPK nucleotide diphosphate kinase, hENT1 
human equilibrative nucleoside transporter-1, hCNT3 human con-
centrative nucleoside transporter-3. In cancer cells, genetic polymor-
phisms affecting membrane transporters, activating and deactivating 
enzymes and pharmacological targets such as ribonucleotide reduc-
tase, are all associated with treatment efficacy
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between dCK activity and gemcitabine sensitivity in tumor 
cells and xenografts [15].
The dynamics of dFdCDP and dFdCTP formation and 
activity in vivo are complex; dFdCTP is incorporated into 
DNA followed by one or more deoxynucleotides masking 
gemcitabine and preventing DNA repair by 3′5′-exonucle-
ase activity, a process designated as “masked DNA chain 
termination” [16]. This causes an S-phase-specific cell 
cycle arrest and programmed cell death. dFdCTP is also 
incorporated into RNA, thus inhibiting RNA synthesis [17], 
while dFdCDP inhibits RR, inducing a depletion of the cel-
lular pool of deoxynucleoside triphosphates, and blocks the 
de novo DNA synthesis pathway [18].
However, only a proportion of gemcitabine is converted 
into the active di- or triphosphate forms. The majority 
of gemcitabine is rapidly inactivated in the liver and to a 
lesser extent in blood by deamination into dFdU, through 
a reaction catalyzed by CDA. Additionally, 10 % of 
unchanged gemcitabine can undergo renal filtration, and 
within 1 week, more than 90 % of the injected dose is usu-
ally recovered in the urine, either as parent gemcitabine 
(1 %) or dFdU (99 %) [19]. In addition, the formation of 
dFdCTP and dFdCDP from dFdCMP is reduced through 
deamination of dFdCMP to 2′,2′-difluorodeoxyuridine 
monophosphate (dFdUMP) by dCMP deaminase. Notably, 
an elevated concentration of dFdCTP inhibits dCMP deam-
inase, determining a “self-potentiation” of the drug activ-
ity [20], which is also caused by the increase in dFdCTP 
accumulation induced by dFdU in a time-dependent man-
ner [21]. dFdCTP also inhibits CTP synthetase, affect-
ing RNA synthesis by depletion of CTP, while the latter 
decreases dCTP synthesis [22, 23]. Finally, a recent study 
demonstrated that gemcitabine can inhibit the enzyme thy-
midylate synthase presumably through the phosphorylated 
metabolite dFdUMP. Inhibition of this enzyme enhances 
the mis-incorporation of 2′-deoxyuridine into DNA, caus-
ing indirect damage [24].
A considerable inter-patient variability has been 
described in gemcitabine accumulation, and the pharma-
cokinetics of gemcitabine and its main metabolite dFdU 
in plasma have been evaluated in multiple studies. Gem-
citabine plasma concentrations generally reach a plateau 
after 15–30 min during the standard 30 min infusion proto-
col. Linear pharmacokinetics have been described over the 
range 40–3650 mg/m2, and nonlinear pharmacokinetics at 
higher doses [19, 25, 26]. Mean gemcitabine peak plasma 
concentrations ranged from 24 μM at 800 mg/m2 [27] to 
32 μM at 1000 mg/m2 [28], around 53–70 μM at a dose 
of 1250 mg/m2 [29, 30], 68–79 µM at 2350 mg/m2 and 
between 320 and 512 µM at the MTD of 5700 mg/m2 [19]. 
Up to at least at gemcitabine 1250 mg/m2, deamination was 
linear with mean plasma dFdU concentrations being 1.25 
times higher as compared to dFdU levels using gemcitabine 
1000 mg/m2. Linearity was lost at doses higher than 
3650 mg/m2 [19]. The clearance of gemcitabine in the 
plasma is also rapid (i.e., T1/2 of 5–20 min). More than 
75 % of gemcitabine is metabolised to dFdU and excreted 
in the urine in the first 24 h [19]. This clearance is inde-
pendent of dose over the linear range (i.e., up to 3650 mg/
m2), but proportional to creatinine clearance. At the high-
est doses, the clearance was lower; moreover, the clearance 
was 1.5-fold higher in men (8.6 l/m2) compared to women 
(5.7 l/m2) [19]. The pharmacokinetic elimination half-life 
for dFdU varies between 2 and 24 h, and it is still present 
systemically in concentrations greater than 1 μM up to 
1 week after dosing [31]. Of note, since dFdU is not pro-
tein bound, its plasma concentration, up to 460 μM [19], 
depending on the dose administered, is freely available. 
These concentrations are cytotoxic [20, 32] and could have 
significant implications in the clinical use of gemcitabine 
alone or in combination with other therapies, such as radia-
tion [33], since dFdU has a radiosensitizing effect by itself.
Since gemcitabine is often given in combination with 
other cytotoxic and targeted drugs, the effect of combina-
tion therapy on the pharmacokinetics has been investigated 
in several clinical studies, since theoretically co-medication 
can affect both drug metabolism and elimination. How-
ever, in the most widely used combination with cisplatin 
or paclitaxel, no evidence was found for an effect of these 
drugs (as well as oxaliplatin and carboplatin) on both gem-
citabine and dFdU pharmacokinetics, investigated within 
the same patients and between patients [27, 28, 30, 34, 
35]. Similarly, the proteasome inhibitor bortezomib and the 
farnesyltransferase inhibitor SCH66336 did not affect the 
pharmacokinetics of gemcitabine or dFdU, alone or in the 
combination with cisplatin [36, 37]. Moreover, no effect of 
the VEGFR inhibitor SU5416 was observed [29], while the 
EGFR inhibitor gefitinib tended to increase the exposure to 
gemcitabine [38]. However, the other EGFR inhibitor erlo-
tinib did not affect pharmacokinetics of the gemcitabine 
prodrug LY2334737 itself or of gemcitabine and dFdU 
[39]. Hence, from the point of view of pharmacokinetics, 
it can be concluded that in general gemcitabine can safely 
be combined with other drugs, both other cytotoxics and 
novel targeted drugs. Naturally, this does not exclude that 
gemcitabine affects the mechanism of action of other drugs 
or that these other drugs affect intracellular metabolism 
of gemcitabine. Two examples include the potentiation by 
gemcitabine of cisplatin adduct formation and the selective 
effect of bortezomib on intracellular gemcitabine activation 
[27, 40].
Less data are available on the pharmacokinetics of 
dFdCTP, which should be measured with more sensitive 
LCMS assays [41]. However, several studies demonstrated 
that cells exposed to gemcitabine have saturable accumula-
tion of the dFdCTP, and the optimal plasma concentration 
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of gemcitabine that maximized the rate of formation of 
dFdCTP was approximately 20 μmol/l [42, 43]. This is 
accompanied by a change in the pattern of elimination with 
monophasic elimination at low concentrations and biphasic 
elimination described after the threshold has been reached.
Since the optimal intracellular accumulation of dFdCTP 
was achieved with dose rates of 10 mg/m2/min [25, 43], 
a number of phase I trials have explored the possibility 
to prolong the duration of infusion time, while other tri-
als escalated both the dose and infusion duration [25, 44, 
45]. The rationale for prolonged dosing received a major 
boost when a randomised phase II trial in a clinically rel-
evant scenario (pancreatic cancer) demonstrated that pro-
longed infusion at a rate of 10 mg/m2/min, compared to the 
standard dosing regimen with 30 min infusion, was asso-
ciated with increased accumulation of dFdCTP, as well as 
with a significant increase in response rate and a trend for 
increased survival [46]. Similar trials in different tumor 
types confirmed the pharmacokinetic finding, but were 
underpowered to demonstrate survival differences [47]. 
Unfortunately, a large phase III study in pancreatic cancer 
showed that the pharmacological advantage failed to trans-
late into a significant survival advantage [34].
Collectively, these clinical studies indicate that the anti-
tumor effect of gemcitabine is schedule dependent and 
that lower doses can be efficacious. Therefore, it could be 
advantageous to deliver gemcitabine in a manner where it 
can achieve prolonged systemic exposure, good efficacy 
with lower toxicity along with added flexibility of admin-
istration and greater patient convenience, such as using an 
oral formulation [48]. However, administering gemcitabine 
orally to patients has been limited by low oral bioavailabil-
ity, high first-pass clearance, variable systemic exposures 
during dose escalation studies and observation of gastroin-
testinal toxicity including nausea, vomiting and diarrhea.
Dysregulation at the germinal level: 
pharmacogenetics of gemcitabine
Factors extracted from either clinical or pathological data 
such as age, performance status, comorbidity and disease 
stage or grade provide a crude discrimination of prognosis, 
but are often not predictive and not helpful for the choice 
of the best chemotherapeutic regimen for a given patient. 
Novel approaches to stratify patient’s prognosis or toxicity 
may be offered by pharmacogenetic analyses of selected 
candidate polymorphisms that could influence the expres-
sion of genes involved in drug metabolic pathways.
Historically, pharmacogenetics is indeed defined as the 
study of germline mutations (e.g., single-nucleotide poly-
morphisms affecting genes coding for enzymes responsible 
for drug pharmacokinetics), whereas pharmacogenomics 
refers to the role of both acquired and inherited genetic 
differences in relation to drug behavior through a system-
atic examination of genes, gene products and inter- and 
intra-individual variation in gene expression and function 
using new genomic technologies [49]. However, in oncol-
ogy, pharmacogenetics is often considered as concerning 
the individual patient’s features and pharmacogenomics as 
those of the tumor.
CDA deregulations and clinical outcome
Gemcitabine is primarily detoxified in the liver by CDA 
into dFdU, with a Km of approximatively 96 µM [50, 51]. 
Usually, 90 % of gemcitabine is detoxified by CDA, and 
variations in enzymatic activity impact greatly on drug 
pharmacokinetics and pharmacodynamics. Mice with 
impaired CDA displayed sharp overexposure to the drug 
with subsequent unrecoverable hematological toxicities 
[52], thus highlighting the correlation between CDA defi-
ciency, overexposure to gemcitabine and increased risk 
of severe toxicities. Indeed, a variety of studies and case 
reports have found a correlation between CDA deficiency 
syndrome and an increase in severe hematological toxici-
ties in patients undergoing gemcitabine-based therapy [52, 
53]. Of note, the first-ever reported case of toxic death 
related to CDA deficiency in an ovarian cancer patient 
treated with the gemcitabine—carboplatin was published 
in 2007 [53]. Profound functional deficiency was retro-
spectively evidenced, with heterozygous CDA*2 genotype. 
Subsequent genetic investigations revealed a new intronic 
mutation (i.e., 154 + 37G>A) on the CDA gene, likely to 
have caused the lethal toxicities [54]. Of note, other stud-
ies have shown that patients with lower CDA activity 
also tend to display higher response rates and better sur-
vival [55, 56]. On the contrary, it has been observed that 
about 15 % of the Caucasian adult population display CDA 
activities significantly higher than the median values of 
adult populations (i.e., over 6 U/mg), making them prone 
to therapeutic failure because most of standard dosing of 
gemcitabine will be metabolized in the liver before it even 
reaches the tumor tissues [52]. A pilot study involving 40 
patients treated by gemcitabine-based regimens for pancre-
atic cancer confirmed that patients displaying CDA ultra-
metabolizer phenotype were fivefold more at risk to have a 
progressive disease than patients with normal CDA status 
[57]. As expected, these patients had milder toxicities than 
patients with normal or lower CDA activity, an observation 
completely in line with previous reports about CDA and 
gemcitabine-related toxicities. Overall, all these studies, 
conducted by independent groups and involving patients 
treated with gemcitabine used alone or in a combination for 
a variety of settings, demonstrate how CDA status greatly 
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affects clinical outcome in patients undergoing gemcit-
abine-based treatments.
CDA genetic polymorphisms
CDA is coded by the 4-exons gene CDA located on the first 
pair of chromosomes (1p36.2-p35). CDA is formed by four 
identical subunits, all presenting a zinc atom in the active 
site. It is mostly expressed in liver and placenta, but high 
levels of CDA are also expressed in mature neutrophils and 
erythrocytes [58]. CDA is responsible for the physiological 
deamination of cytidine and 2′-deoxycytidine into uridine 
and 2′-deoxyuridine, respectively. Because a wide inter-
patient variability has been observed with CDA, numerous 
studies have been undertaken to screen for possible muta-
tions and polymorphisms affecting the CDA gene since the 
mid-70s, both in germinal cells and in cancer cells [59–62]. 
As of today, up to 1000 genetic variations affecting CDA 
have been described. The most studied polymorphisms are 
the two non-synonymous 79A>C (rs2072671) and 208G>A 
(rs60369023) substitutions and the synonymous 435C>T 
(rs1048977) variant [63–66]. Beside these polymorphisms 
affecting coding regions, many other mutations of the pro-
moter region such as the −31delC deletion (rs3215400) 
or −92A>G (rs602950), or in intronic regions such as the 
154 + 37G>A polymorphism (rs12059454) have been 
described [54, 67–70]. All these genetic variations lead 
to inconsistent and sometimes conflictual results in term 
of resulting phenotypic status [69, 70], as reported in the 
Table 1.
Indeed, the large inter-individual variability reported 
with CDA activity is only partly explained by the genetic 
background. In addition, because more than 1000 genetic 
variations have been evidenced, SNP-candidate studies 
are probably underpowered strategies, yielding conflict-
ual data [51, 55, 64, 68, 71, 72]. For instance, the 79A>C 
polymorphism (i.e., CDA*2) leads to lysine to glutamine 
permutation in position 27, with no impact on the catalytic 
site eventually, but other factors might play a role. Of note, 
ethnicity plays a crucial role in the allelic frequencies of 
this variant because minor allele frequency (MAF) ranges 
from 10 % in African population, 15 % in Asian popula-
tion, but up to 35 % in Caucasians [73, 74]. The phenotypic 
impact of this allelic variant and its consequence in the 
clinical outcome in patients treated with nucleoside ana-
logs remain controversial: a decrease in CDA activity has 
been measured for the Lys27Lys variant [75, 76], whereas 
other studies suggest no variation [52, 77] or lower activ-
ity for the Gln27Gln variant [78, 79]. These differences may 
be partly explained by variations in study design such as 
patient selection, ethnicity and treatment regimens [80–82]. 
A pivotal study has recently been published, collecting data 
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natural and synthetic [83]. This biochemical study, inspired 
from a previous work in 2012 by Baker and collaborators 
[79], highlights that catalytic efficiency of CDA enzyme is 
dependent on the genetic sequence encoding for the pro-
tein, but also on the drugs used as substrates. Surprisingly, 
an increase in CDA catalytic efficiency was observed for 
the CDA27Gln protein with natural cytidine analogs and 
cytarabine, but surprisingly a decrease was found for other 
substrates such as 5-azacytidine, 6-azacytidine and fazara-
bine. This is in agreement with the results of the study by 
Giovannetti et al. [75], in which CDA27Gln activity was 
investigated with gemcitabine, with a decrease in deami-
nase activity being observed with this polymorphism.
In addition to the CDA*2 allelic variant, another poly-
morphism has been studied extensively: CDA*3, resulting 
from the substitution of alanine to threonine in position 70 
because of the 208G>A SNP in the coding sequence. With 
the CDA*3 variant, impact on CDA phenotype is more uni-
vocal because researchers all agree that a decrease in CDA 
activity is found for the protein encoded by 208 A/A vari-
ant [68, 74, 83]. Indeed, deaminase activity was found to be 
100-fold lower than normal CDA with respect to all tested 
drugs with this allelic variant [57]. Of note and unlike 
CDA*2, which is found in every population, but in differ-
ent proportions, CDA*3 has never been detected in Cauca-
sian populations, but is only found in Africans and Asians. 
To date, the clinical impact of CDA*3 genotype in patients 
treated with gemcitabine has been repeatedly reported in 
Japanese patients only [74, 83, 84]. In addition, two studies 
have aimed at establishing the respective MAF of 79A>C, 
208G>A and 435C>T in both Asian and Caucasian popula-
tions [67, 85]. Few differences were observed in MAF of 
435C>T allelic variant when comparing these two ethnici-
ties, whereas discrepancies were evidenced for the 79A>C 
and 208G>A variants. For the CDA*2 allelic variant, twice 
as many individuals carry a wild-type genotype with a 
lower incidence of C/C genotype in Asians, as compared 
with white people. The discrepancy is more marked for the 
rs60369023 variant because no individual, whether in Afri-
can-Americans, Chinese-Americans, or Caucasian-Amer-
icans, was carrying the minor allele A. Only 11 patients 
were heterozygous among over 400 Korean and Japanese 
patients, and none of them was found to be homozygous for 
the CDA*3 variant [85]. These data confirm that screening 
for 208G>A single-nucleotide polymorphism has a clini-
cal, yet limited, meaning in Asian or more significantly in 
Japanese populations only. As mentioned above, numerous 
other genetic variations have been identified, but no study 
has established a clear link between a given genotype and 
the resulting phenotype yet, apart for the −31delC variant 
(rs532545), a CDA promoter deletion possibly resulting 
in an amplification of the CDA gene with functional (i.e., 
ultrametabolizer phenotype) impact eventually [71]. These 
data call for more sophisticated multigenic or haplotype-
based studies to establish a clear genotype-to-phenotype 
relationship with CDA and gemcitabine.
Dysregulation at the tumor level: 
pharmacogenomics of gemcitabine
Several determinants for efficacy have been identified 
with gemcitabine at the tumor level. Because gemcitabine 
requires facilitated transport for cellular uptake [11], sev-
eral studies evaluated the expression levels of the plasma 
membrane human equilibrative nucleoside transporter-1 
(hENT1) and human concentrative nucleoside transporter-3 
(hCNT3), showing their prognostic and predictive roles of 
drug activity in patients undergoing gemcitabine-based reg-
imen [86–89]. Higher uptake in cancer cells with high lev-
els of both transporters could explain the marked increase 
in disease-free survival and overall survival observed in 
pancreatic cancer patients administered with gemcitabine. 
Of note, several polymorphisms affecting the genes coding 
for hENT1 and hCNT3 have been described. These poly-
morphisms might impact protein expression, but the func-
tional and clinical significance of these polymorphisms 
have yet to be defined [10].
Other determinants for response at the tumor level 
include the expression of dCK, the rate-limiting enzyme 
activating the prodrug gemcitabine to active nucleotides 
[90], deoxycytidylate deaminase that metabolizes active 
phosphorylated nucleotides into inactive metabolites [6] 
and RR that is one of the gemcitabine targets [91]. These 
genes have many polymorphisms, which could impact on 
drug efficacy, but the relevance of all these markers has not 
been fully confirmed at the bedside. Large prospective con-
trol studies are necessary to confirm the role of these deter-
minants in response to gemcitabine.
However, the candidate-gene approach used in most of 
these studies cannot establish if a positive association is 
due to linkage with untyped functional variant alleles or 
due to intragene interaction. Drug efficacy and toxicity may 
also be influenced by other genes and pathways, which will 
be undetected by single-polymorphism analysis. Therefore, 
alternative approaches through the broader application of 
new genomic technologies might be necessary to identify 
novels biomarkers of gemcitabine efficacy and toxicity, 
and to bring us closer to tailor-made therapy for individual 
patients [92]. Li et al. [93] used such a method to identify 
novel genes involved in gemcitabine metabolism. After 
analyzing data with 26,653 probe sets, the researchers iden-
tified 15 genes where mRNA expression correlated with 
cytidine analog sensitivity and, from there, selected FKBP5 
for further functional variation. FKBP5 is a gene involved 
in steroid receptor mutation and is a binding partner for 
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rapamycin, suggesting that it may have a role in the apop-
tosis pathway. Overexpression of FKBP5 correlated with 
increased gemcitabine chemosensitivity. Using FKBP5 
siRNA-treated cells, the researchers showed a decrease in 
downstream enzyme caspase-3/7 activity, confirming that 
the activation of the apoptotic pathway was affected by the 
downregulation of FKBP5 expression.
Recently, it has also been shown that tumor blood perfu-
sion and vessels’ density could be associated with response 
to drug-based therapy, probably in relation with a drug 
delivery issue. In this respect, the Hedgehog signaling 
pathway has been suggested as being a new determinant 
of response with gemcitabine, since it is associated with 
production of a desmoplastic tumor stroma and a reduced 
tumoral perfusion eventually, probably through the expres-
sion of Gli family transcriptor factors. As a result, Hedge-
hog signaling could prevent at least partly gemcitabine to 
be delivered to tumors [94, 95]. This rising concern in both 
experimental and clinical oncology about the role Hedge-
hog protein plays, highlights the fact that beyond pharma-
cological molecular determinants, the issue of drug deliv-
ery becomes more and more critical [96, 97]. This issue 
is currently addressed by recent efforts to develop “gem-
citabine 2.0.” forms likely to display improved distribution 
and cellular uptake profiles.
Gemcitabine prodrugs
In order to overcome various forms of drug resistance and/
or to improve drug delivery, recent studies evaluated sev-
eral gemcitabine prodrugs. Since many clinical studies 
showed that a low expression of hENT1 was associated 
with a poor survival of pancreatic cancer patients receiving 
gemcitabine [97–99], Clavis Pharma developed an elaidic 
acid prodrug modified at the 5′-sugar position, CP-4126, 
which was able to bypass hENT1. CP-4126 was similarly 
effective as gemcitabine in various model systems in vivo 
and showed an oral efficacy, possibly because CP-4126 
could also inhibit CDA, preventing or reducing its first-
pass effect [98]. Because of its efficacy in phase II stud-
ies, CP-4126 (as CO-101) was tested in a phase II rand-
omized, multicenter trial in comparison with gemcitabine 
as first-line therapy in metastatic pancreatic cancer patients 
[99]. Mandatory tumor biopsy specimens were evaluated 
for their hENT1 expression in both treatment groups. The 
similar effect of CO-101 and gemcitabine demonstrated an 
effective conversion of the prodrug to gemcitabine. How-
ever, the study did not reach its anticipated endpoint, an 
increased efficacy of CO-101 compared to gemcitabine 
in the low hENT1 group of patients. Of note, no differ-
ence in survival was found also between the low and high 
hENT group treated with gemcitabine, suggesting that the 
role of hENT1 is less important in metastatic disease than 
after surgery, as shown in the patients in the earlier adju-
vant studies. However, it is also possible that the lack of 
difference between the patients with low and high hENT1 
expression was due to a lower specificity of the antibody, 
which was different from that used in earlier studies.
Another gemcitabine prodrug currently in clinical devel-
opment is LY2334737, which has valproic acid attached to 
the N4 of the base. Valproic acid is cleaved off by carboxy-
lesterase 2 (CES2), which is high in the liver and gastroin-
testinal tract, resulting in an early cleavage of the molecule, 
as well as in a better antitumor activity in tumors with a 
high CES2 activity. A phase I dose-finding study with oral 
administration (daily for 14 days, with 1 week rest) showed 
linear pharmacokinetics, until the maximal tolerated dose 
of 40 mg in Caucasian and 30 mg in Japanese patients, with 
a lower toxicity profile compared to oral gemcitabine [39, 
100]. However, using other schedules (every other day for 
21 days followed by 1 week rest, or daily for 7 days every 
other week), the maximal tolerated dose was 90 mg/m2, 
which was recommended for phase II studies for the every 
other day schedule [101].
Nucana developed another type of prodrug, NUC-1031, 
which is a gemcitabine analog to which a phosphorami-
date ProTide moiety has been added. This novel nucleotide 
evades all three main cellular resistance mechanisms asso-
ciated with gemcitabine (i.e., nucleoside transport, dCK-
mediated activation and CDA-mediated degradation). NUC-
1031 showed activity in cell culture and in in vivo models, 
including xenografts resistant to systemic gemcitabine treat-
ment, while dFdCTP reaching tenfold higher levels in white 
blood cells than was found for gemcitabine at similar doses 
[102, 103]. More recently, NUC-1031 showed clear signs of 
clinical activity in patients with gynecological cancers. This 
agent was well tolerated, and a phase Ib study of NUC-1031 
in combination with carboplatin is ongoing, while phase III 
studies are planned in both platinum sensitive and refractory 
gynecological cancers [104].
Another approach to increase delivery consists in the 
use nanoparticles that can be designed to allow controlled/
sustained drug release [105]. These systems are more sta-
ble than liposomes, but retain their low immunogenic-
ity. Gemcitabine-loaded gold nanoparticles targeted to 
the epidermal growth factor receptor with cetuximab had 
an increased targeting and activity of gemcitabine in pan-
creatic tumors in vitro and in mouse tumor models [106]. 
Similarly, gemcitabine covalently coupled with the natural 
lipid 1,1′,2-tris-nor-squalenic acid (squalene) at its 4-amino 
moiety, resulting in 4-(N)-tris-nor-squalenoyl-gemcitabine, 
which spontaneously assemble into a hexagonal structure 
with an aqueous core, was active in both human and murine 
leukemia resistant cell lines and tumors [107].
8 Cancer Chemother Pharmacol (2016) 78:1–12
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Gemcitabine can also be covalently coupled via poly-
ethylene glycol (PEG) to another molecule that can target 
the complex to tumor cells, such as for PEG-gemcitabine 
conjugates to folic acid, binding specifically to the folate 
receptors, which are highly overexpressed on the surface 
of many cancers [108]. Finally, gemcitabine can also be 
loaded in PEGylated liposomes [109].
Conclusions and perspectives
There are few drugs in oncology that are as old, but still 
so widely used as chemotherapeutic targets such as gem-
citabine. Gemcitabine is indeed approved and commonly 
used, alone or in combination, for the treatment of several 
tumor types, such as NSCLC, pancreatic, bladder, ovarian 
and breast cancer. In order to improve its antitumor activ-
ity while reducing toxic effects, many studies investigated 
pharmacokinetics [110] and/or the impact of genetic pol-
ymorphisms and CDA activity [51, 55], as well as tumor-
specific expression of hENT1 mRNA and protein [87, 88], 
on gemcitabine toxicity and efficacy. These factors appear 
to be the most promising predictive indicators of outcome 
in patients receiving gemcitabine chemotherapy [9, 10].
However, most pharmacogenetic studies were retro-
spective and monocentric, without multiple correction and 
validation in broader populations. Most phenotypic stud-
ies used different methods and specimens; for example, a 
number of assays have been used to determine CDA activ-
ity in various blood compartments [111]. Moreover, most 
clinical trials on gemcitabine combinations were performed 
without previous preclinical studies evaluating molecular 
mechanisms and markers of drug synergistic interaction, 
while pharmacogenomics studies on tumor specimens did 
not evaluate tumor heterogeneity and possible evolution of 
cancer cells after tumor relapse, which should be faithfully 
documented within multiple samples of the single tumor as 
well as repeated biopsies.
Therefore, future efforts should be redirected at iden-
tifying, both in preclinical models and in the clinical set-
ting, either sensitive or non-responding genotypes or phe-
notypes. These profiles should be identified with validated 
methods, which should be used for the appropriate patient 
enrollment into subsequent prospective studies.
Hopefully, in the near future, the availability of validated 
genetic/phenotypic platforms will lead to the selection of 
key factors responsible of the chemosensitivity and toxicity 
to gemcitabine-based treatments and guide in the choice of 
more effective rationally based tailor-made treatments for 
each patient.
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